These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 12886864)

  • 41. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
    J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of hereditary breast and ovarian cancer.
    Yamauchi H; Takei J
    Int J Clin Oncol; 2018 Feb; 23(1):45-51. PubMed ID: 29185095
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
    Grenader T; Peretz T; Lifchitz M; Shavit L
    Breast; 2005 Aug; 14(4):264-8. PubMed ID: 16085232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prophylactic surgery for women at high risk for breast cancer.
    Blanchard DK; Hartmann LC
    Clin Breast Cancer; 2000 Jul; 1(2):127-34; discussion 135. PubMed ID: 11899651
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Perspectives in the clinical management of BRCA mutations carriers.
    Savarese A; Cognetti F
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
    Grann VR; Panageas KS; Whang W; Antman KH; Neugut AI
    J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations.
    Haber D
    N Engl J Med; 2002 May; 346(21):1660-2. PubMed ID: 12024000
    [No Abstract]   [Full Text] [Related]  

  • 49. Prophylactic oophorectomy in women at increased cancer risk.
    Domchek SM; Rebbeck TR
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.
    Salhab M; Bismohun S; Mokbel K
    BMC Womens Health; 2010 Oct; 10():28. PubMed ID: 20961453
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.
    Ludwig KK; Neuner J; Butler A; Geurts JL; Kong AL
    Am J Surg; 2016 Oct; 212(4):660-669. PubMed ID: 27649974
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations.
    Metcalfe KA
    Womens Health (Lond); 2009 Jan; 5(1):63-8. PubMed ID: 19102642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer.
    Hermsen BB; van Diest PJ; Berkhof J; Menko FH; Gille JJ; Piek JM; Meijer S; Winters HA; Kenemans P; Mensdorff-Pouilly Sv; Verheijen RH
    Int J Cancer; 2006 Sep; 119(6):1412-8. PubMed ID: 16615107
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Choice of management of southern Chinese BRCA mutation carriers.
    Kwong A; Wong CH; Shea C; Suen DT; Choi CL
    World J Surg; 2010 Jul; 34(7):1416-26. PubMed ID: 20182723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations.
    Olopade OI; Artioli G
    Breast J; 2004; 10 Suppl 1():S5-9. PubMed ID: 14984481
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations.
    Roukos DH; Agnanti NJ; Paraskevaidis E; Kappas AM
    Ann Surg Oncol; 2002 Dec; 9(10):941-3. PubMed ID: 12464584
    [No Abstract]   [Full Text] [Related]  

  • 58. BRCA mutation genetic testing implications in the United States.
    Bayraktar S; Arun B
    Breast; 2017 Feb; 31():224-232. PubMed ID: 27931006
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [INSERM-FNCLCC collective expert's report. Recommendations for management of women having a genetic risk of developing breast and/or ovarian cancer. National Federation of Centers of the Fight Against Cancer].
    Eisinger F; Alby N; Bremond A; Dauplat J; Espié M; Janiaud P; Kuttenn F; Lebrun JP; Lefranc JP; Pierret J; Sobol H; Stoppa-Lyonnet D; Thouvenin D; Tristant H; Feingold J
    Ann Endocrinol (Paris); 1998; 59(6):470-84. PubMed ID: 10189990
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome.
    Batista LI; Lu KH; Beahm EK; Arun BK; Bodurka DC; Meric-Bernstam F
    BMC Cancer; 2008 Apr; 8():101. PubMed ID: 18410690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.